View all SABCS CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Acknowledgment of Commercial Support

Supported by educational grants from AbbVie, Astellas Pharma, and Medivation, Inc.


Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future - PER Pulse™ Recap
PER Pulse™ Recap

Resources

Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future
Earn up to 1.5 AMA PRA Category 1 Credits™
This activity focuses on triple-negative breast cancer, and features a series of short video interviews with leading experts in the treatment of breast cancer. The content and interviews are based on presentations given at Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future, a CME-certified, ancillary satellite symposium held in San Antonio, Texas.

PER Pulse™ Recap
PER Pulse™ Recaps for Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future focuses on a series of video interviews with leading experts in the treatment of triple-negative breast cancer that are featured in an online CME activity currently available at www.gotoper.com.



PER Pulse™ Recap

PER Pulse™ Recap
 


1 of 3
PER Pulse™ Recap

Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future is a series of short video interviews with the faculty of a CME-certified satellite symposium held December 2015 in San Antonio, TX. In this online activity, leaders in breast cancer discuss recent and emerging advances in the management of triple-negative breast cancer (TNBC). It features commentary by William Gradishar, MD, on real-world scenarios; Hope Rugo, MD, on novel approaches for the basal-like subtype; Tiffany Traina, MD, on strategies for luminal/apocrine subtypes; and Jenny Chang, MD, on novel therapeutic hypotheses. Joyce O'Shaughnessy, MD, provides a summary and reviews take-home points to finish the activity.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Gradishar's interview. Chemotherapy is the standard of care for TNBC in both the perioperative and advanced settings. No TNBC-specific regimens or agents have been defined or recommended, to date. In his video interviews, Dr. Gradishar discusses the following:
  • Chemotherapy as the standard of care for TNBC
  • Renewed interest in the use of DNA-damaging agents for TNBC, such as platinum chemotherapy, and ongoing studies in this area
  • When he might consider use of a platinum agent for TNBC in the adjuvant and metastatic settings
  • The standard of care, emerging strategies, and unmet needs of patients found to have significant residual disease after preoperative therapy
  • Related take-home points from the panel discussion that took place at the live event on which this online activity is based

2 of 3
PER Pulse™ Recap

Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future is a series of short video interviews with the faculty of a CME-certified satellite symposium held December 2015 in San Antonio, TX. In this online activity, leaders in breast cancer discuss recent and emerging advances in the management of triple-negative breast cancer (TNBC). It features commentary by William Gradishar, MD, on real-world scenarios; Hope Rugo, MD, on novel approaches for the basal-like subtype; Tiffany Traina, MD, on strategies for luminal/apocrine subtypes; and Jenny Chang, MD, on novel therapeutic hypotheses. Joyce O'Shaughnessy, MD, provides a summary and reviews take-home points to finish the activity.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Traina's interview. Molecular profiling of breast tumor samples has provided the rationale for clinical investigation of therapeutic androgen receptor (AR) inhibition for estrogen receptor-negative (ER-) breast cancer. In her interview, Dr. Traina discusses the following:
  • The significance of new data related to AR-positive TNBC that is or is likely to become therapeutically relevant. For example, she comments that:
    • The subset of patients with TNBC that is AR-driven may be larger than anticipated.
    • The 35% clinical benefit rate observed in a phase II clinical study of enzalutamide is encouraging for a well-tolerated hormonal agent in patients with TNBC.
  • Her current approach toward AR screening and clinical trial enrollment for patients with AR-positive breast cancer.
  • Strategies being investigated for AR-positive TNBC include not only AR inhibition alone, but also dual inhibition with inhibitors of CYP17, CDK4/6, or PI3K.
  • No standardized test exists for AR expression at the protein level; however, results from ongoing efforts to develop a validated clinical AR biomarker have been encouraging.

3 of 3
PER Pulse™ Recap

Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future is a series of short video interviews with the faculty of a CME-certified satellite symposium, held December 2015, in San Antonio, TX. In this online activity, leaders in breast cancer discuss recent and emerging advances in the management of triple-negative breast cancer (TNBC). It features commentary by William Gradishar, MD, on real-world scenarios; Hope Rugo, MD, on novel approaches for the basal-like subtype; Tiffany Traina, MD, on strategies for luminal/apocrine subtypes; and Jenny Chang, MD, on novel therapeutic hypotheses. Joyce O'Shaughnessy, MD, provides a summary and reviews take-home points to finish the activity.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Chang's interview. The heterogeneity of TNBC poses significant challenges to researchers and clinicians. Ongoing work aims to individualize therapy based on molecular subtypes and exploit subtype-specific abnormalities. In her presentation to the working group and during her interview, Dr. Chang discusses the following:

  • The potential for patient-derived tumor xenograft models to enable more accurate assessment of clinical potential of investigational agents (vs conventional cell line models).
  • The possibility that pan-histone deacetylase inhibition can sensitize nonBRCA1-mutated TNBC cells to a PARP inhibitor of platinum agent.
  • That a subset of patients may harbor paradoxical activation of HER2-family signaling that is independent of total HER2 protein levels. Preliminary data support investigation of combined targeting across HER-family receptors.
  • Promising results from early trials of a first-in-class antibody-drug conjugate, sacituzumab govitecan (IMMU-132) in TNBC.
  • Phase I data from clinical trials of immune checkpoint-blocking agents pembrolizumab and atezolizumab.


Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Supported by educational grants from AbbVie, Astellas Pharma, and Medivation, Inc.
 





Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By